The recalled injections include glutathione, Myer’s Cocktail, and Tri-Immune Boost products marketed for wellness purposes, including immunity support, fatigue-related concerns, dehydration and general health uses. The Food and Drug Administration said the affected products may expose patients to risks linked to endotoxins if they are injected.
FDA Identifies Affected Products and Potential Health Risks
According to the Food and Drug Administration notice dated Sept. 13, 2026, Centric Compounding issued a nationwide recall after an ingredient used in the injectable products was found to contain elevated levels of endotoxins. These substances are toxins released by certain bacteria and can trigger serious reactions when introduced into the body through injection.
The FDA said possible reactions linked to endotoxin exposure include fever, low blood pressure, inflammatory responses, anaphylactic shock and death. Centric Compounding reported nine adverse reaction cases as of the FDA notice, with consumers experiencing symptoms including fever, chills, chest pain, nausea or vomiting, headache and a general feeling of illness.
The recalled products include three lots of Glutathione 200mg/ml 30mL vials, two lots of Myer’s Cocktail 30mL vials and one lot of Tri-Immune Boost 30mL vials. The products were distributed nationwide through home delivery and to prescribers.
The affected glutathione lots include 062326:B, expiring Aug. 7, 2026; 070826:A, expiring Aug. 22, 2026; and 072726:D, expiring Sept. 25, 2026. The recalled Myer’s Cocktail lots are 070226:D, expiring Aug. 16, 2026, and 072126:A, expiring Sept. 4, 2026. The Tri-Immune Boost lot is 071626:B, expiring Aug. 30, 2026.
Consumers who have these products are advised to stop using them and discard them immediately. Centric Compounding said it is contacting customers and distributors and arranging replacements for recalled products.
The Recall Highlights Questions Surrounding Compounded Medicines
Compounding pharmacies prepare customized medications by combining ingredients to meet specific patient needs. According to Harvard Health, these pharmacies may be used when a patient requires a different dosage, a different form of a medication or a formulation that removes certain allergens.
Unlike commercially manufactured drugs, compounded medicines are not reviewed by the FDA for purity, safety or effectiveness before use. According to Harvard Health, compounded drugs must contain FDA-approved ingredients, but the final formulations prepared by compounding pharmacies do not undergo the same approval process as mass-produced medications.
The FDA and healthcare organizations have previously raised concerns about contamination risks involving compounded sterile products. The Centers for Disease Control and Prevention documented a 2012 outbreak of fungal infections linked to contaminated steroid injections produced by a compounding pharmacy, with hundreds of illnesses reported.
Patients with questions about the current recall can contact Centric Compounding by phone at 833-777-6664 or by email at [email protected]. The FDA recommends that people experiencing possible side effects contact their healthcare provider and report adverse events through its MedWatch reporting program.
